Cellectis Announces Arbitral Decision in Servier Dispute

Cellectis SA ( (CLLS) ) has provided an announcement.

On December 15, 2025, Cellectis announced an arbitral decision regarding its dispute with Servier over a License, Development, and Commercialization Agreement from 2019. The Tribunal partially terminated the agreement concerning the UCART19 V1 product, allowing Cellectis to engage in discussions for a direct license with Allogene. All other claims were dismissed, impacting Cellectis’ operational strategy and potential market collaborations.

The most recent analyst rating on (CLLS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.

Spark’s Take on CLLS Stock

According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.

Cellectis SA’s overall stock score is primarily influenced by its strong technical indicators, which suggest positive market momentum. However, the company’s financial performance and valuation are concerning due to persistent unprofitability and negative cash flow, which significantly impact the score.

To see Spark’s full report on CLLS stock, click here.

More about Cellectis SA

Cellectis is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on allogeneic approaches for CAR T immunotherapies in oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment. Cellectis is one of the few companies that manages the entire cell and gene therapy value chain, with headquarters in Paris and additional locations in New York and Raleigh, NC. It is publicly traded on the Nasdaq Global Market and Euronext Growth.

Average Trading Volume: 149,122

Technical Sentiment Signal: Buy

Current Market Cap: $347.9M

Learn more about CLLS stock on TipRanks’ Stock Analysis page.